INKT, reduction in the operating behavior throughout the fiscal fourth quarter of 2022

As the October to December 31 2022 reporting cycle goes on, countless corporations have declared the respective numbers. Among them, are various companies in the Biotechnology & Pharmaceuticals sector. As well as, today, INKT announced operating shortfall of $-7.889209 million, for the fiscal span closing Dec 31 2022.

The good effort to relate the fiscal fourth quarter of 2022 result, at the recent situation of the business. Currently, it is straight forward to correlate the operating surplus of the fourth quarter of 2021, which came in $13.376434 million.


Even though, the income in the current situation of the business has, the subordinate position. It is vital to claim, that the Mink Therapeutics Inc has dealt with a loss of $-7.770 million, in the fiscal fourth quarter of 2022, while INKT has been above break-even in the fourth quarter of 2021.

Furthermore, the Mink Therapeutics Inc indicated as well a shortfall of $-27.99 million and for the fiscal year 2022, revenue of $0.00 million.

Biotechnology & Pharmaceuticals Mink Therapeutics Inc has decreased it's loss per share to $-0.83 from $-1.16 in the previous fiscal year, while by 0 % from $0.00 million a year before.

Mink Therapeutics Inc is expected to report next financial recent numbers on May 12, 2023.

Mink Therapeutics Inc's Net Profit Margin

Mink Therapeutics Inc's Dividend Comparisons

Other INKT's Earnings Reports

Mink Therapeutics Inc reported Q3 of 2022 earnings

Mink Therapeutics Inc reported Q2 of 2022 earnings

Mink Therapeutics Inc reported Q1 of 2022 earnings